Publication Author: Kessler_Larry

• The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines.

  Gold LS, Klein G, Carr L, Kessler L, Sullivan SD. The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines. Cancer Imaging. 2012 Jan 25;12(1):13-24.

  rakerr2

  January 25, 2012

• A framework for assessing the value of diagnostic imaging in the era of comparative effectiveness research.

  Gazelle GS, Kessler L, Lee DW, McGinn T, Menzin J, Neumann PJ, van Amerongen D, White LA; Working Group on Comparative Effectiveness Research for Imaging. A framework for assessing the value of diagnostic imaging in the era of comparative effectiveness re

  rakerr2

  December 1, 2011

• Influence of publication of US and European prostate cancer screening trials on PSA testing practices.

  Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 2011 Mar 16;103(6):520-3. Epub 2011 Feb 28.

  rakerr2

  March 16, 2011

• Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration.

  Regnier FE, Skates SJ, Mesri M, Rodriguez H, Tezak Z, Kondratovich MV, Alterman MA, Levin JD, Roscoe D, Reilly E, Callaghan J, Kelm K, Brown D, Philip R, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Ransohoff DF, Mansfield

  rakerr2

  February 1, 2010

• Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics.

  Rodriguez H, Tezak Z, Mesri M, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Philip R, Ransohoff DF, Skates SJ, Regnier FE, Anderson NL, Mansfield E; Workshop Participants. Analytical validation of protein-based multiplex a

  rakerr2

  February 1, 2010

• Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization.

  Miglioretti DL, Rutter CM, Bradford SC, Zauber AG, Kessler LG, Feuer EJ, Grossman DC. Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care. 2008 Sep;46(9 Suppl 1):S91-6.

  rakerr2

  September 1, 2008

• The forest and the trees: the human costs of cancer.

  Kessler LG, Ramsey SD. The forest and the trees: the human costs of cancer. J Natl Cancer Inst. 2007 Jan 3;99(1):2-3.

  rakerr2

  January 3, 2007

• The US Food and Drug Administration perspective on cancer biomarker development.

  Gutman S, Kessler LG. The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer. 2006 Jul;6(7):565-71. Review.

  rakerr2

  July 1, 2006

• The impact of comorbidities on hormone use. After the 2000 release of the Women’s Health Initiative.

  Newton KM, Buist DS, Miglioretti DL, Beverly K, Hartsfield CL, Chan KA, Andrade SE, Wei F, Connelly MT, Kessler L. The impact of comorbidities on hormone use. After the 2000 release of the Women’s Health Initiative. J Gen Intern Med. 2005 Apr;20(4):350-6.

  rakerr2

  April 1, 2005

• Hormone therapy prescribing patterns in the United States.

  Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, Hartsfield CL, Wei F, Chan KA, Kessler L. Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004 Nov;104(5 Pt 1):1042-50.

  rakerr2

  November 1, 2004